Journal Article
. 2014 Mar;110(8).
doi: 10.1038/bjc.2014.156.

Adaptive designs for clinical trials assessing biomarker-guided treatment strategies

J Wason 1 A Marshall 2 J Dunn 2 R C Stein 3 N Stallard 4 
Affiliations
  • PMID: 24667651
  •     25 References
  •     8 citations

Abstract

Background: The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to either receive the standard chemotherapy treatment or a biomarker-directed treatment arm, in which biomarker status is used to guide treatment.

Methods: Motivated by a current trial, we consider an adaptive design in which two biomarkers are assessed. The trial is conducted in two stages. In the first stage, patients in the biomarker-guided arm are assessed using a standard and an alternative cheaper biomarker, with the standard biomarker guiding treatment. An analysis comparing biomarker results is then used to choose the biomarker to use for the remainder of the trial. The new biomarker is used if the results for the two biomarkers are sufficiently similar.

Results: We show that in practical situations the first-stage results can be used to adapt the trial without type I error rate inflation. We also show that there can be considerable cost gains with only a small loss in power in the case where the alternative biomarker is highly concordant with the standard one.

Conclusions: Adaptive designs have an important role in reducing the cost and increasing the clinical utility of trials evaluating biomarker-guided treatment strategies.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Clinical trial designs for predictive marker validation in cancer treatment trials.
Daniel J Sargent, Barbara A Conley, Carmen Allegra, Laurence Collette.
J Clin Oncol, 2005 Mar 19; 23(9). PMID: 15774793
Highly Cited. Review.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
A mixed approach for proving non-inferiority in clinical trials with binary endpoints.
Valentin Rousson, Burkhardt Seifert.
Biom J, 2008 Mar 04; 50(2). PMID: 18311852
Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue.
Lida Mina, Sharon E Soule, +8 authors, Kathy D Miller.
Breast Cancer Res Treat, 2006 Oct 14; 103(2). PMID: 17039265
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
John M S Bartlett, Jeremy Thomas, +12 authors, Udi Chetty.
Breast Cancer Res, 2010 Jul 10; 12(4). PMID: 20615243    Free PMC article.
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Jenny C Chang, Andreas Makris, +14 authors, Steven Shak.
Breast Cancer Res Treat, 2007 May 01; 108(2). PMID: 17468949
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
Xian Zhou, Suyu Liu, +2 authors, J Jack Lee.
Clin Trials, 2008 Jun 19; 5(3). PMID: 18559407    Free PMC article.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.
Brian Z Ring, Robert S Seitz, +9 authors, Douglas T Ross.
J Clin Oncol, 2006 Jul 01; 24(19). PMID: 16809728
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
Sumithra J Mandrekar, Daniel J Sargent.
J Clin Oncol, 2009 Jul 15; 27(24). PMID: 19597023    Free PMC article.
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.
Richard Simon.
Per Med, 2010 Apr 13; 7(1). PMID: 20383292    Free PMC article.
Randomized clinical trials with biomarkers: design issues.
Boris Freidlin, Lisa M McShane, Edward L Korn.
J Natl Cancer Inst, 2010 Jan 16; 102(3). PMID: 20075367    Free PMC article.
Highly Cited.
Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.
J Bartlett, P Canney, +19 authors, R Stein.
Clin Oncol (R Coll Radiol), 2012 Dec 27; 25(2). PMID: 23267818
Review.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Daniel Ontaneda, Robert J Fox, Jeremy Chataway.
Lancet Neurol, 2015 Mar 17; 14(2). PMID: 25772899    Free PMC article.
Highly Cited. Review.
Clinical trial designs incorporating predictive biomarkers.
Lindsay A Renfro, Himel Mallick, +2 authors, Sumithra J Mandrekar.
Cancer Treat Rev, 2016 Feb 02; 43. PMID: 26827695    Free PMC article.
Review.
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Miranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-Dona.
PLoS One, 2016 Feb 26; 11(2). PMID: 26910238    Free PMC article.
Review.
Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.
Yunee Kim, Jouhyun Jeon, +10 authors, Thomas Kislinger.
Nat Commun, 2016 Jun 29; 7. PMID: 27350604    Free PMC article.
Imaging biomarker roadmap for cancer studies.
James P B O'Connor, Eric O Aboagye, +74 authors, John C Waterton.
Nat Rev Clin Oncol, 2016 Nov 03; 14(3). PMID: 27725679    Free PMC article.
Highly Cited. Review.
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Miranta Antoniou, Ruwanthi Kolamunnage-Dona, Andrea L Jorgensen.
J Pers Med, 2017 Jan 27; 7(1). PMID: 28125057    Free PMC article.
Review.
Point estimation following two-stage adaptive threshold enrichment clinical trials.
Peter K Kimani, Susan Todd, Lindsay A Renfro, Nigel Stallard.
Stat Med, 2018 Jun 02; 37(22). PMID: 29855066    Free PMC article.
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.
Thomas Burnett, Pavel Mozgunov, +3 authors, Thomas Jaki.
BMC Med, 2020 Nov 20; 18(1). PMID: 33208155    Free PMC article.